Moderna (NasdaqGS:MRNA) appointed Juan Andres as its first Chief Operating Officer as it reshapes its leadership structure.
Moderna (NasdaqGS:MRNA) entered high-level investment talks with the UAE government on advanced pharmaceutical manufacturing ...
Stocktwits on MSN
SLS, IBRX stocks climb overnight: Retail eyes Moderna’s rally as MRNA lands a Nasdaq-100 spot
SLS investors compared Sellas’ potential with Moderna’s rally, with one saying, “It will be SLS next.” ・IBRX traders weighed ...
Warner Bros. Discovery drops from Nasdaq 100 and S&P 500 as $81B Paramount merger closes. Moderna and Twilio fill the vacancies next week.
Modernas cancer-vaccine program is driving renewed market attention. Its mRNA platform extends beyond COVID-19 vaccines. Clinical progress remains central to the companys evolving story. Modernas ...
Moderna stock has rallied since the company unveiled clinical updates to its cancer vaccine in collaboration with Merck in ...
Shares of Moderna (MRNA +2.08%) jumped during the COVID-19 pandemic, but when its COVID-19 vaccine revenue dried up, the stock slumped. However, the company has recently shown it isn't a one-trick ...
Moderna ( ) just unveiled an update. On September 1, 2026, Moderna completed a $3.0 billion private offering of 0.00% Convertible Senior Notes due 2032, issued as senior unsecured ...
Moderna (MRNA) is rated Sell due to overextended valuation post-melanoma Phase 3 trial news, with a fair value estimate near $110 versus ~$145 trading price. Current market pricing assumes de-risked ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results